Serum thymidine kinase activity as a "real-time" clinical biomarker of tumor response to CDK4/6 inhibition in hormone receptor positive (HR+), HER2 negative (HER2-) metastatic breast cancer

被引：0
|
作者：
Bagegni, Nusayba
Williams, Amy
Grigsby, Isabella
Bergqvist, Mattias
Clifton, Katherine
Ma, Cynthia
机构：
来源：
CANCER RESEARCH | 2024年 / 84卷 / 09期
关键词：
D O I：
10.1158/1538-7445.SABCS23-PO1-15-06
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
PO1-15-06
引用
收藏
页数：3
相关论文
共 50 条
  • [41] Patterns of treatment and outcome of palbociclib plus endocrine therapy in hormone receptor-positive (HR+)/HER2 receptor-negative (HER2-) metastatic breast cancer (MBC): A real life multicenter Italian study
    Palumbo, R.
    Torrisi, R.
    Quaquarini, E.
    Sottotetti, F.
    Gambaro, A.
    Collova, E.
    Ferzi, A.
    Fava, S.
    Agostinetto, E.
    Tagliaferri, B.
    Licata, L.
    Teragni, C.
    Bernardo, A.
    CANCER RESEARCH, 2019, 79 (04)
  • [42] The clinical impact of NOLUS in unresectable/metastatic hormone receptor-positive (HR+)/HER2-negative breast cancer
    Tajiri, Wakako
    Nakamura, Yoshiaki
    Kawasaki, Junji
    Koi, Yumiko
    Akiyoshi, Sayuri
    Koga, Chinami
    Tokunaga, Eriko
    CANCER RESEARCH, 2024, 84 (09)
  • [43] Hormone receptor-positive HER2-low metastatic breast cancer (mBC): evolution of HER2 status after CDK4/6 inhibitor treatment
    de Nonneville, Alexandre
    Finetti, Pascal
    Boudin, Laurys
    Usclade, Lucas
    Mescam, Lenaig
    Durieux, Emeline
    Boucraut, Agathe
    Viret, Frederic
    Mamessier, Emilie
    Goncalves, Anthony
    Bertucci, Francois
    CANCER RESEARCH, 2024, 84 (09)
  • [44] Real-World Experience with CDK4/6 Inhibitors for Metastatic HR+/HER2-Breast Cancer at a Single Cancer Center
    Knudsen, Erik S.
    Schultz, Emily
    Hamilton, Deanna
    Attwood, Kris
    Edge, Stephen
    O'Connor, Tracey
    Levine, Ellis
    Witkiewicz, Agnieszka K.
    ONCOLOGIST, 2022, 27 (08): : 646 - 654
  • [45] MINERVA - Combination of Abemaciclib and endocrine therapy in hormone receptor positive (HR+) HER2 negative (HER2-) locally adv./metastatic breast cancer with focus on digital side effect management
    Rack, Brigitte
    Uhl, Natalie
    Veselinovic, Kristina
    Degregorio, Amelie
    Friedl, Thomas W. P.
    Pfister, Kerstin
    Fink, Angelina
    Fehm, Tanja
    Huober, Jens
    Janni, Wolfgang
    ONCOLOGY RESEARCH AND TREATMENT, 2022, 45 (SUPPL 3) : 40 - 40
  • [46] Real World Statistics on CDK4/6 Inhibitor Use in Metastatic Hormone Receptor Positive and HER2-Negative Breast Cancer with a Focus on Age
    Monahan, Kathleen
    Kamaraju, Sailaja
    Cheng, Yee Chung
    Retseck, Janet
    Sriram, Deepika
    Burfeind, John
    Chitambar, Christopher
    Chaudhary, Lubna N.
    CANCER RESEARCH, 2023, 83 (05)
  • [47] HEALTHCARE COSTS IN WOMEN WITH HR+/HER2-METASTATIC BREAST CANCER TREATED WITH CDK4/6 INHIBITORS
    Burne, R.
    Balu, S.
    Guerin, A.
    Liang, Y.
    Schloessmann, R.
    Bungay, R.
    Paul, M. L.
    VALUE IN HEALTH, 2020, 23 : S44 - S44
  • [48] Real-world experience with CDK4/6 inhibitors for metastatic HR+/HER2-breast cancer at a single cancer center
    Milovic-Kovacevic, M.
    Bobic, S.
    Karaferic, A.
    Pavlovic, L.
    Matovic, M.
    Poparic-Bandjur, B.
    BREAST, 2023, 68 : S115 - S115
  • [49] Advancing treatment choices: CDK4/6 inhibitor switching in HR+/HER2-metastatic breast cancer
    Zagami, Paola
    Esposito, Angela
    Salimbeni, Beatrice Taurelli
    Giachetti, Pier Paolo Maria Berton
    Scafetta, Roberta
    Lambertini, Matteo
    Di Maio, Massimo
    Curigliano, Giuseppe
    Criscitiello, Carmen
    Cinieri, Saverio
    BREAST, 2025, 79
  • [50] The association of hormone receptor expression level and clinical efficacy of CDK4/6 inhibitor in hormone receptor-positive, HER2-negative metastatic breast cancer
    Bao, Kelvin K. H.
    Wong, Carol H. Y.
    Yung, Jackie
    Tam, Venus
    Cheung, Ka Man
    Chan, Jeffrey C. H.
    Yiu, Harry H. Y.
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
12345